| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ITCH_0027300 | Exon-Exon | chr20:33065577-33092208 | chr20:34477772-34504403 | 920 nt | 0.3891 |
| hsa_ITCH_0027400 | Exon-Exon | chr20:33065577-33099197 | chr20:34477772-34511392 | 250 nt | 0.3160 |
| hsa_ITCH_0028100 | Exon-Exon | chr20:33067435-33069011 | chr20:34479630-34481206 | 435 nt | 0.3609 |
| hsa_ITCH_0029000 | Exon-Exon | chr20:33068404-33069011 | chr20:34480599-34481206 | 275 nt | 0.3491 |
| hsa_ITCH_0029100 | Exon-Exon | chr20:33068404-33099197 | chr20:34480599-34511392 | 250 nt | 0.2960 |
| hsa_ITCH_0030000 | Exon-Exon | chr20:33077071-33080402 | chr20:34489266-34492597 | 323 nt | 0.4056 |
| hsa_ITCH_0030100 | Exon-Exon | chr20:33077071-33092208 | chr20:34489266-34504403 | 396 nt | 0.4091 |
| hsa_ITCH_0030700 | Exon-Exon | chr20:33080306-33092208 | chr20:34492501-34504403 | 170 nt | 0.4118 |
| hsa_ITCH_0000400 | Intron-Exon-Intron | chr20:32951825-32996598 | chr20:34364019-34408792 | 250 nt | 0.3440 |
| hsa_ITCH_0000500 | Intron-Exon-Intron | chr20:32953266-32957276 | chr20:34365460-34369470 | 194 nt | 0.5619 |
A review consolidating research in humans and model organisms indicates that the circITCH functions as a tumor suppressor in glioma by sponging miR-214 to allow expression of ubiquitin-protein ligase E3, thereby suppressing proliferation and preventing apoptosis, while also targeting the Wnt/β-catenin pathway [Mehta et al. DOI:10.1016/j.pneurobio.2020.101746]. In oesophageal squamous cell carcinoma, the circITCH is downregulated and increases ITCH expression to inhibit the Wnt/β-catenin pathway [Lee et al. DOI:10.1016/j.biopha.2018.12.052]. circITCH hsa_circ_0001141 (circITCH) was found to be lower in the hearts of cancer patients suffering from doxorubicin-induced cardiomyopathy compared to those with dilated cardiomyopathy, hypertrophic cardiomyopathy, and healthy donors, and its expression ameliorates doxorubicin-induced cardiomyocyte injury [Tian et al. DOI:10.3390/molecules26041155].